278 results on '"Norman Jaffe"'
Search Results
2. Osteosarcoma: Evolution of Treatment Paradigms
- Author
-
Norman Jaffe, Ajay Puri, and Hans Gelderblom
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
This paper reviews the contribution of chemotherapy in the conquest of osteosarcoma. It discusses how the treatment of osteosarcoma has evolved over the last five decades, resulting in a more than fivefold increase in survival. Though the initial improvements in survival were dramatic, essentially there has been no change in the outlook for this disease over the past 30 years. The paper also highlights the necessity of a multidisciplinary approach to combat this disease and stresses the need to explore newer treatment agents in order to build on the lessons learnt from the past while striving to achieve greater levels of success.
- Published
- 2013
- Full Text
- View/download PDF
3. Residencia de David Reiss Bridgetiampton - Nueva York
- Author
-
Norman Jaffe
- Subjects
Architecture ,NA1-9428 ,Building construction ,TH1-9745 - Abstract
Situada en una parcela próxima a la costa, se trata de una obra claramente representativa de este arquitecto. El conjunto lo componen: la vivienda, una construcción anexa —de menor porte—, y una piscina central rodeada de explanadas y terrazas. La vivienda propiamente dicha consta de tres niveles fundamentales, de los cuales el inferior lo ocupan los dormitorios de los niños, y el central las zonas comunes —estar, cocina y comedor—, reservándose el más alto para el dormitorio principal. A estos niveles se suman una entreplanta vinculada al salón, dedicada a biblioteca, y un semisótano conectado con la cocina que se destina a almacén de provisiones. Los grandes planos inclinados de la cubierta configuran la personalidad exterior de la casa que, con sus formas sobrias y agradables, procura la integración con la rústica arquitectura del entorno. Interiormente destaca el tratamiento liberal dado a los espacios, con circulaciones integradoras, y el abundante empleo de la madera en acabados y estructura.
- Published
- 1979
- Full Text
- View/download PDF
4. m+m: A novel Middleware for Distributed, Movement based Interactive Multimedia Systems.
- Author
-
Ulysses Bernardet, Dhruv Adhia, Norman Jaffe, Johnty Wang, Michael Nixon, Omid Alemi, Jordon Phillips, Steve DiPaola, Philippe Pasquier, and Thecla Schiphorst
- Published
- 2016
- Full Text
- View/download PDF
5. PillowTalk: can we afford intimacy?
- Author
-
Thecla Schiphorst, Frank Nack, Michiel Kauw A Tjoe, Simon de Bakker, Stock, Lora Aroyo, Angel Perez Rosillio, Hielke Schut, and Norman Jaffe
- Published
- 2007
- Full Text
- View/download PDF
6. Applying an Aesthetic Framework of Touch for Table-Top Interactions.
- Author
-
Thecla Schiphorst, Nima Motamedi, and Norman Jaffe
- Published
- 2007
- Full Text
- View/download PDF
7. Exploring touch and breath in networked wearable installation design.
- Author
-
Thecla Schiphorst, Jinsil Seo, and Norman Jaffe
- Published
- 2010
- Full Text
- View/download PDF
8. Using a gestural interface toolkit for tactile input to a dynamic virtual space.
- Author
-
Thecla Schiphorst, Robb Lovell, and Norman Jaffe
- Published
- 2002
- Full Text
- View/download PDF
9. m+m:A novel Middleware for Distributed, Movement based Interactive Multimedia Systems
- Author
-
Philippe Pasquier, Michael Nixon, Johnty Wang, Dhruv Adhia, Ulysses Bernardet, Omid Alemi, Steve DiPaola, Jordon Phillips, Thecla Schiphorst, and Norman Jaffe
- Subjects
020203 distributed computing ,business.industry ,Computer science ,Distributed computing ,Semantic interpretation ,Small footprint ,Internal communications ,020207 software engineering ,02 engineering and technology ,Open source software ,Rendering (computer graphics) ,Software portability ,Human–computer interaction ,Embodied cognition ,0202 electrical engineering, electronic engineering, information engineering ,business ,Interactive media - Abstract
Embodied interaction has the potential to provide users with uniquely engaging and meaningful experiences. m+m: Movement + Meaning middleware is an open source software framework that enables users to construct real-time, interactive systems that are based on movement data. The acquisition, processing, and rendering of movement data can be local or distributed, real-time or off-line. Key features of the m+m middleware are a small footprint in terms of computational resources, portability between different platforms, and high performance in terms of reduced latency and increased bandwidth. Examples of systems that can be built with m+m as the internal communication middleware include those for the semantic interpretation of human movement data, machine-learning models for movement recognition, and the mapping of movement data as a controller for online navigation, collaboration, and distributed performance.
- Published
- 2016
10. Perspectives of the Role of Chemotherapy in the Management of Osteosarcoma
- Author
-
Jyoti Bajpai and Norman Jaffe
- Subjects
Oncology ,medicine.medical_specialty ,Chemotherapy ,Ifosfamide ,Cyclophosphamide ,business.industry ,medicine.medical_treatment ,medicine.disease ,Primary tumor ,Surgery ,Amputation ,Internal medicine ,Localized disease ,medicine ,Osteosarcoma ,Methotrexate ,business ,medicine.drug - Abstract
Background: Multimodality management of osteosarcoma has significantly improved the 5-year-survival rate for localized disease over the past 40 years: from 5% - 10% (in historical controls) to 65% - 75% and 20% - 30% in metastatic disease. These results were achieved with doxorubicin, cisplatin, high-dose methotrexate and ifosfamide (or cyclophosphamide). In the absence of new and effective agents the results have remained stationary for at least the past 30 years. No standard second line therapy exists for patients who relapse. In these circumstances surgery when feasible, constitutes the main therapeutic option. Questions/Purposes: To understand the present approach to therapy and determine the possibilities for improvement a review of the chemotherapeutic agents currently deployed in the treatment of Osteosarcoma was undertaken. Methods: The review focused on the results achieved with the evolution of therapy following the discovery of effective chemotherapeutic agents. Results: There was an improvement in survival during the first decade following the introduction of effective chemotherapy and limb salvage replaced amputation in the majority of patients. Attempts to rescue pulmonary metastases patients with surgical intervention were also enhanced but produced only minor improvement in survival. An international collaborative study, EURAMOS has been launched to investigate the utility of neoadjuvant chemotherapeutic agents in improving survival based upon their efficacy in the treatment of the primary tumor. Conclusions: New agents and or new strategies are urgently required to improve the outcome in Osteosarcoma.
- Published
- 2012
11. COMPARISON OF DOXORUBICIN CARDIOTOXICITY IN PEDIATRIC SARCOMA PATIENTS WHEN GIVEN WITH DEXRAZOXANE VERSUS AS CONTINUOUS INFUSION
- Author
-
Mark F. Munsell, Jean-Bernard Durand, Cynthia E. Herzog, Winston W. Huh, and Norman Jaffe
- Subjects
Adult ,Male ,Adolescent ,Anthracycline ,Bone Neoplasms ,Cohort Studies ,Electrocardiography ,Young Adult ,Risk Factors ,Ventricular Dysfunction ,medicine ,Humans ,Doxorubicin ,Child ,Infusions, Intravenous ,Retrospective Studies ,Osteosarcoma ,Cardiotoxicity ,Ejection fraction ,business.industry ,Retrospective cohort study ,Hematology ,medicine.disease ,Oncology ,Child, Preschool ,Heart failure ,Anesthesia ,Pediatrics, Perinatology and Child Health ,Female ,Dexrazoxane ,Sarcoma ,Razoxane ,business ,medicine.drug - Abstract
Doxorubicin is an effective agent for many malignancies. To limit cardiotoxicity, doxorubicin can be given as prolonged infusion (PIDX) or bolus infusion following dexrazoxane (DZX). The authors report their institutional experience comparing PIDX and DZX in a sarcoma cohort. Retrospective record review for newly diagnosed sarcoma patients at the University of Texas M.D. Anderson Cancer Center from June 1998 to June 2006. There were 23 Ewing's sarcoma (EWS) patients treated with DZX and 40 osteosarcoma (OS) patients treated with PIDX. The DZX group had higher mean cumulative anthracycline dose (510 mg/m(2) [SD 120 mg/m(2)] versus 414 mg/m(2) [SD 99 mg/m(2)], P = .002), however mean lowest left ventricular ejection fraction (EF) values were higher for DZX (52.5% [SD 5.6%] versus 47.2% [SD 10.9%], P = .014). Fifteen of 19 patients with cardiac dysfunction were PIDX patients (P = .15). Five PIDX patients required cardiac medication, and 1 patient died of congestive heart failure (CHF). Sixteen patients with cardiac dysfunction had improvement, demonstrated by EF ≥ 50% at last echocardiogram. Although not statistically significant, there were 4 DZX patients with cardiac dysfunction. Prospective studies are required to determine which strategy has long-term advantages and if certain patients are at increased risk for cardiac dysfunction.
- Published
- 2010
12. Psychosocial and functional outcomes in long-term survivors of osteosarcoma: A comparison of limb-salvage surgery and amputation
- Author
-
Giulia Ottaviani, Shana L. Palla, Winston W. Huh, Norman Jaffe, and Rhonda Robert
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Cancer ,Hematology ,medicine.disease ,Surgery ,Social support ,Patient satisfaction ,Oncology ,Amputation ,Quality of life ,Survivorship curve ,Pediatrics, Perinatology and Child Health ,Physical therapy ,Medicine ,Young adult ,business ,Psychosocial - Abstract
Background Traditionally, physicians have believed that limb-salvage surgery has functional and cosmetic advantages over amputation, yet the literature is equivocal. Therefore, we sought to compare the psychosocial and functional outcomes in osteosarcoma survivors after limb-salvage surgery and amputation. We hypothesized there to be neither psychosocial nor functional outcome differences between groups. Procedure Participants received treatment of extremity osteosarcoma, had received their cancer diagnosis at least 2 years prior, and were at least 16 years old. A comprehensive set of validated psychosocial and functional measures was used to assess outcome. Results Fifty-seven patients participated in this study (33 who underwent limb-salvage surgery and 24 who underwent amputation). Participants had gone 12–24 years since diagnosis and were 16–52 years old at study participation. We used multiple linear regression models to examine differences in quality of life, body image, self-esteem, and social support between the two groups and found no differences. Lower limb function was a significant predictor of quality of life (P
- Published
- 2010
13. Chemotherapy response is an important predictor of local recurrence in ewing sarcoma
- Author
-
Jeana S. Kelly, Colleen M. Costelloe, Patrick P. Lin, Shreyaskumar Patel, Robert S. Benjamin, John E. Madewell, Cynthia E. Herzog, Valerae O. Lewis, Michael T. Deavers, Norman Jaffe, Christopher P. Cannon, and Alan W. Yasko
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Surgical margin ,Adolescent ,Bone Neoplasms ,Sarcoma, Ewing ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Child ,Survival rate ,Aged ,Neoplasm Staging ,Univariate analysis ,business.industry ,Proportional hazards model ,Infant ,Cancer ,Middle Aged ,Prognosis ,medicine.disease ,Combined Modality Therapy ,Primary tumor ,Surgery ,Radiography ,Survival Rate ,Treatment Outcome ,Oncology ,Child, Preschool ,Female ,Radiology ,Sarcoma ,Neoplasm Recurrence, Local ,Positive Surgical Margin ,business ,Follow-Up Studies - Abstract
BACKGROUND. Local recurrence in Ewing sarcoma is associated with a poor prognosis. The purpose of the study was to determine the factors that predict local recurrence after surgical treatment of the primary tumor. METHODS. Between 1990 and 2001, 64 patients underwent surgical resection of Ewing sarcoma. Surgical margins were assessed histologically and radiologically. Response to preoperative chemotherapy was determined by detailed specimen mapping. Local recurrence-free survival (LRFS) was calculated by Kaplan–Meier analysis. Multivariate analysis was performed with the Cox proportional hazards model. RESULTS. A number of factors were found to be associated with local recurrence on univariate analysis. Patients with a good response to chemotherapy (≥90% tumor necrosis), had superior LRFS at 5 years (86% vs 51%, P = .015). Central site of disease was associated with an increased rate of recurrence. The LRFS at 5 years was 50% for the chest wall, 74% for pelvic/scapular, and 86% for extremity tumors (P = .083). Positive surgical margin was not a strong predictor of recurrence (P = .72). A critical analysis of minimal surgical margin based on preoperative magnetic resonance imaging (MRI) and computed tomography (CT) scans also failed to reveal an association between margin and local recurrence. In multivariate analysis, the 2 independent predictors of local recurrence were histological response to chemotherapy and central site of disease. CONCLUSION. Local recurrence after surgical resection is a complex phenomenon. An important predictive factor is the response to chemotherapy. In the current study, this seems to have the largest impact. Central site of disease may be a second independent predictive factor. Cancer 2007;109:603–611. © 2006 American Cancer Society.
- Published
- 2007
14. Chemotherapy-Irradiation Related Hepatic Dysfunction in Patients with Wilms� Tumor1
- Author
-
J. Robert Cassady, Steven C. Carabell, and Norman Jaffe
- Published
- 2015
15. Malignant Bone Tumors in Children
- Author
-
Norman Jaffe
- Subjects
Pathology ,medicine.medical_specialty ,business.industry ,medicine ,business - Published
- 2015
16. Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcoma
- Author
-
Charles S. Cox, Matthew T. Harting, Norman Jaffe, Kevin P. Lally, Martin L. Blakely, Robert S. Benjamin, Andrea Hayes-Jordan, A. Kevin Raymond, and Richard J. Andrassy
- Subjects
Adult ,Male ,medicine.medical_specialty ,Lung Neoplasms ,Adolescent ,medicine.medical_treatment ,Bone Neoplasms ,Disease-Free Survival ,Pneumonectomy ,Humans ,Medicine ,Thoracotomy ,Child ,Retrospective Studies ,Osteosarcoma ,Chemotherapy ,business.industry ,Infant, Newborn ,Infant ,Retrospective cohort study ,General Medicine ,medicine.disease ,Primary tumor ,Confidence interval ,Surgery ,Treatment Outcome ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Female ,Metastasectomy ,business ,Follow-Up Studies - Abstract
Although survival without resection of pulmonary metastases from osteosarcoma is unlikely, not all surgeons agree on an aggressive surgical approach. We have taken an approach to attempt surgical resection if at all feasible regardless of number of metastases and disease-free interval (DFI). This study presents information on long-term follow-up after this aggressive approach to resection.A single-institution retrospective cohort study of osteosarcoma patients younger than 21 years with pulmonary metastases, limited to the contemporary chemotherapeutic period (1980-2000), was conducted.In 137 patients, synchronous (23.4%) or metachronous (76.6%) pulmonary nodules were identified. The median follow-up was 2.0 years (5 days to 20.1 years) for all patients. Overall survival among patients who had pulmonary nodules was 40.2% and 22.6% at 3 and 5 years, respectively. Ninety-nine patients underwent attempted pulmonary metastasectomy (mean survival, 33.6 months; 95% confidence interval, 25.1-42.1) and 38 patients did not (mean survival, 10.1 months; 95% confidence interval, 6.5-13.6; P.001, t test). Characteristics that were associated with an increased likelihood of 5-year overall survival after pulmonary resection were primary tumor necrosis greater than 98% after neoadjuvant chemotherapy (P.05) and DFI before developing lung metastases more than 1 year (P.001). No statistically significant difference in overall survival or disease-free survival was found based on the number of pulmonary metastases resected. Characteristics including primary tumor size, site, or extension; chemotherapy; early vs late metastases; unilateral vs bilateral metastases; and resection margins did not significantly affect survival.Most patient and tumor characteristics commonly used by surgeons to determine utility of resection of pulmonary metastases among patients with osteosarcoma are not associated with outcome. Biology of the particular tumor (response to preoperative chemotherapy, measured by tumor necrosis percentage, and DFI), as opposed to tumor burden, appears to influence survival more significantly. We would advocate considering repeat pulmonary resection for patients with recurrent metastases from osteosarcoma.
- Published
- 2006
17. Ewingʼs Sarcoma of the Mobile Spine
- Author
-
Ziya L. Gokaslan, Rex A.W. Marco, Laurence D. Rhines, J. Brett Gentry, J. P. Wolinski, Valerae O. Lewis, and Norman Jaffe
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Kyphosis ,Cauda equina syndrome ,Sarcoma, Ewing ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Orthopedics and Sports Medicine ,Child ,Survival rate ,Retrospective Studies ,Spinal Neoplasms ,Dose-Response Relationship, Drug ,Radiotherapy ,business.industry ,Laminectomy ,Ewing's sarcoma ,Retrospective cohort study ,Decompression, Surgical ,medicine.disease ,Combined Modality Therapy ,Magnetic Resonance Imaging ,Surgery ,Radiography ,Radiation therapy ,Treatment Outcome ,Female ,Neurology (clinical) ,Sarcoma ,Neoplasm Recurrence, Local ,business - Abstract
Study design A retrospective analysis was performed. Objectives To determine the oncological outcome of patients with nonmetastatic Ewing's sarcoma of the mobile spine treated with systemic multiagent chemotherapy combined with radiation therapy for definitive local control. Summary of background data To our knowledge, there are no studies that evaluate the oncological outcome of patients with nonmetastatic Ewing's sarcoma of the mobile spine treated with systemic chemotherapy and radiation therapy for definitive local control. Methods Thirteen patients with nonmetastatic Ewing's sarcoma of the mobile spine were treated with high-dose multiagent chemotherapy combined with radiation therapy for definitive local control from 1971 to 2000 at a single institution. Patients were observed for a minimum of 2 years or until death. Neurological function, local recurrence, distant relapse, and treatment-related complications were evaluated. Results There were 8 females and 5 males with a mean age of 19 years (ranging from 7-26 years). The mean follow-up time was 65 months (median 28 months; ranging from 2 to 218 months). All patients presented with pain. Motor deficits were present in 6 patients. Ten patients had a decompressive laminectomy. Improved pain control, as determined by narcotic use, was noted in 12 (92%) patients. Ten patients maintained or improved motor function by at least 1 Frankel grade, while 3 had deterioration of motor function. The disease-free survival rate was 49% and 36% at 5 and 10 years. Five (38%) patients were free of disease at last follow-up. Seven patients developed metastatic disease. Three (23%) patients developed a local recurrence. One of these patients had paraplegia associated with the local recurrence. Five patients developed 8 treatment-related complications. Four of the 10 (40%) patients that had a laminectomy developed progressive kyphosis. Two of these patients also developed late-onset cauda equina syndrome along with the deformity. One of these patients also developed cardiomyopathy associated with adriamycin cardiotoxicity. One patient developed a nonhealing pressure ulcerover a prominent spinous process. Conclusions The current study provides historical data on a relatively homogeneous group of patients withEwing's sarcoma of the mobile spine treated with multiagent chemotherapy combined with radiation therapy for definitive local control. Systemic chemotherapy combined with current spinal resection and reconstruction techniques may lead to improved oncological and clinical outcomes.
- Published
- 2005
18. Recurrent osteosarcoma with a single pulmonary metastasis: a multi-institutional review
- Author
-
Carlos Rodriguez-Galindo, Bhaskar N. Rao, Paul A. Meyers, Winston W. Huh, Norman Jaffe, Alexander J. Chou, Catherine A. Billups, and Najat C. Daw
- Subjects
Oncology ,Male ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,recurrence ,Adolescent ,nodule ,medicine.medical_treatment ,Bone Neoplasms ,Disease ,thoracotomy ,chemotherapy ,Disease-Free Survival ,lung ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Thoracotomy ,Young adult ,Child ,030304 developmental biology ,Retrospective Studies ,0303 health sciences ,Chemotherapy ,Osteosarcoma ,Lung ,solitary ,business.industry ,Retrospective cohort study ,medicine.disease ,Prognosis ,3. Good health ,medicine.anatomical_structure ,Treatment Outcome ,030220 oncology & carcinogenesis ,Clinical Study ,Female ,Metastasectomy ,Neoplasm Recurrence, Local ,business ,metastasectomy - Abstract
Background: Late relapse and solitary lesion are positive prognostic factors in recurrent osteosarcoma. Methods: We reviewed the records of 39 patients treated at three major centres for recurrent osteosarcoma with a single pulmonary metastasis more than 1 year after diagnosis. We analysed their outcomes with respect to clinical factors and treatment with chemotherapy. Results: Median age at diagnosis was 14.6 years. Relapse occurred at a median of 2.5 years (range, 1.2–8.2 years) after initial diagnosis. At relapse, all patients were treated by metastasectomy; 12 (31%) patients also received chemotherapy. There was no difference in time to recurrence or nodule size between the patients who received or did not receive chemotherapy at relapse. Sixteen patients had no subsequent recurrence, 13 of whom survive without evidence of disease. The 5-year and 10-year estimates of post-relapse event-free survival (PREFS) were 33.0±7.5% and 33.0±9.6%, respectively, and of post-relapse survival (PRS) 56.8±8.6% and 53.0±11.0%, respectively. There was a trend for nodules
- Published
- 2014
19. Historical perspective on the introduction and use of chemotherapy for the treatment of osteosarcoma
- Author
-
Norman, Jaffe
- Subjects
Osteosarcoma ,Lung Neoplasms ,Drug Administration Routes ,Bone Neoplasms ,History, 20th Century ,History, 21st Century ,Drug Administration Schedule ,Methotrexate ,Treatment Outcome ,Chemotherapy, Adjuvant ,Doxorubicin ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Ifosfamide ,Cisplatin ,Cyclophosphamide - Abstract
Chemotherapy for treatment of osteosarcoma was demonstrated to be effective in eradicating primary tumor and pulmonary metastases in the mid-twentieth century. The first agents that held promise were doxorubicin and high-dose methotrexate with leucovorin (citrovorin factor) in the mid-1970s. Since then, other agents that can eliminate or cause regression of tumor have been discovered: cis-diamminedichloroplatinum II (cisplatin) and the oxazaphosphorines ifosfamide and cyclophosphamide. Additional agents await further study to define their potential. The effective agents have been utilized in various combination regimens and have escalated the survival rate from10 to 75 %. They have also enabled pulmonary metastectomy in patients with persistent and/or recurrent pulmonary metastases and tumor ablation and limb salvage in 80 % of newly diagnosed patients. Unfortunately, however, despite these impressive advances no change in survival expectancy of patients with osteosarcoma during the past 40 years has occurred. There have been no new chemotherapeutic agents effective in addressing disease that is resistant to current agents; the few that have been introduced await further study to substantiate their efficacy. This also includes attempts at alternate administration of chemotherapy (intra-arterial and inhalation therapy.) In this chapter, we provide an account of the sequential introduction of the chemotherapeutic agents, review the results of their application in selected regimens, and discuss the role of neoadjuvant chemotherapy.
- Published
- 2014
20. Malignant bone tumors
- Author
-
Norman Jaffe
- Subjects
Pathology ,medicine.medical_specialty ,business.industry ,Pediatrics, Perinatology and Child Health ,medicine ,business - Published
- 2014
21. Historical Perspective on the Introduction and Use of Chemotherapy for the Treatment of Osteosarcoma
- Author
-
Norman Jaffe
- Subjects
Oncology ,medicine.medical_specialty ,Chemotherapy ,Ifosfamide ,Cyclophosphamide ,business.industry ,medicine.medical_treatment ,medicine.disease ,Primary tumor ,Internal medicine ,medicine ,Osteosarcoma ,Doxorubicin ,business ,Survival rate ,Neoadjuvant therapy ,medicine.drug - Abstract
Chemotherapy for treatment of osteosarcoma was demonstrated to be effective in eradicating primary tumor and pulmonary metastases in the mid-twentieth century. The first agents that held promise were doxorubicin and high-dose methotrexate with leucovorin (citrovorin factor) in the mid-1970s. Since then, other agents that can eliminate or cause regression of tumor have been discovered: cis-diamminedichloroplatinum II (cisplatin) and the oxazaphosphorines ifosfamide and cyclophosphamide. Additional agents await further study to define their potential. The effective agents have been utilized in various combination regimens and have escalated the survival rate from
- Published
- 2014
22. Osteosarcoma in Preadolescent Patients
- Author
-
Norman Jaffe, M Johnson, A W Yasko, A. K. Raymond, James L. Murray, Alberto G. Ayala, Peggy Pearson, and M Rytting
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Long bone ,Bone Neoplasms ,Disease-Free Survival ,Pelvis ,law.invention ,Necrosis ,Randomized controlled trial ,law ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Orthopedics and Sports Medicine ,Child ,Neoadjuvant therapy ,Survival analysis ,Osteosarcoma ,business.industry ,Medical record ,Extremities ,General Medicine ,medicine.disease ,Combined Modality Therapy ,Survival Analysis ,Neoadjuvant Therapy ,Surgery ,Clinical trial ,medicine.anatomical_structure ,Female ,business ,Follow-Up Studies - Abstract
The medical records of boys younger than 11 years and girls younger than 10 years of age with osteosarcoma of the pelvis or extremity were reviewed. Thirty patients were identified who were newly diagnosed but untreated for osteosarcoma. None of these patients had pulmonary metastases. The same four protocols were used to treat the patients in the current study as were used to treat adolescents. The event-free and overall survival was calculated and prognostic factors were assessed. The median followup time was 8 years (range, 6-14 years). The results were compared with the results of older patients treated with the same protocols and with published results. Fourteen patients had pulmonary metastases (47%); among these patients, four also had skeletal metastases (in two of the latter, skeletal metastases appeared before the pulmonary metastases). Event-free survival was 53% and overall survival was 57%. This result is comparable with current survival results in adolescent and older patients. Serum alkaline phosphatase and serum lactic dehydrogenase levels before treatment, height percentile greater than 50%, chemotherapy-induced tumor necrosis, surgical procedure, tumor site, tumor histologic features, and patient gender were not prognostic indicators. The prognosis for prepubertal patients with osteosarcoma is similar to the prognosis of their adolescent and older counterparts. There does not seem to be any indication to treat preadolescent patients with osteosarcoma using alternate therapies.
- Published
- 2000
23. Osteopenia in young adult survivors of childhood cancer
- Author
-
Rena Vassilopoulou-Sellin, Hallie Zietz, Abraham S. Delpassand, Mary Jean Klein, Norman Jaffe, and Patrick G. Brosnan
- Subjects
musculoskeletal diseases ,Peak bone mass ,Cancer Research ,medicine.medical_specialty ,Pediatrics ,Bone density ,Bone disease ,business.industry ,Osteoporosis ,Cancer ,medicine.disease ,Surgery ,Osteopenia ,medicine.anatomical_structure ,Oncology ,Pediatrics, Perinatology and Child Health ,medicine ,Young adult ,business ,Femoral neck - Abstract
Background Improved survival of children with malignant diseases is in part due to the application of intensive, multimodality therapies, including radiotherapy, surgery, glucocorticoids, and cytotoxic agents. Such interventions have the potential to induce complex hormonal, metabolic and nutritional effects that may interfere with skeletal mass acquisition during childhood and adolescence: it is possible that such childhood cancer survivors may therefore reach adulthood with diminished peak bone mass and be at increased risk for clinically significant osteoporosis later in their life. Procedure A bone mineral density (BMD) was measured in 26 unselected former cancer patients attending the Pediatric Long-Term Clinic at M.D. Anderson Cancer Center. BMD was measured at the lumbar spine and the hip using dual X-ray absorptiometry (Hologic QDR-4500W). In addition, the patients' complete medical records were reviewed with particular attention to disease type, age modalities of treatment, and hormonal residual deficiencies. Results The median age of patients at the time of cancer diagnosis was 8 years (range, 0.3 to 16 years). Median age at BMD determination was 23 years (range, 18 to 41 years), and the median interval since cancer diagnosis and BMD was 18 years (range, 5 to 29). Overall, their BMD was decreased relative to peak bone mass at all sites: osteopenia was especially pronounced in patients with a history of cranial irradiation who had developed evidence of pituitary insufficiency during childhood or adolescence. Overall, the median BMD T-score was −1.41 at the lumbar spine, −1.04 at the femoral neck, and −1.06 for total hip. For patients with prior cranial irradiation, T-score at the lumbar spine was −2.18 (range, −4.06 to −0.98), at the femoral neck −1.92 (range, −4.11 to +1.10), and for total hip −1.67 (range, −4.79 to +0.56); BMD for irradiated patients was significantly lower than BMD of patients without cranial irradiation. We could not discern an independent impact of other disease characteristics or treatment modalities in this small group of patients. Conclusions Osteopenia is a prominent finding in young adults who are survivors of childhood cancers; it is likely that antineoplastic treatments during childhood and adolescence impede peak bone mass acquisition. We suggest that systematic attention to this potential complication is needed in order to identify what subgroups of children may require regular surveillance and what interventions are required for its prevention or treatment. Med. Pediatr. Oncol. 32:272–278, 1999. © 1999 Wiley-Liss, Inc.
- Published
- 1999
24. Doxorubicin cardiotoxicity in children: Comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration
- Author
-
Robert S. Benjamin, Hallie Zietz, Hubert L. Ried, Michael S. Ewer, and Norman Jaffe
- Subjects
Cancer Research ,Cardiotoxicity ,Chemotherapy ,business.industry ,Incidence (epidemiology) ,medicine.medical_treatment ,medicine.disease ,Regimen ,Oncology ,Anesthesia ,Heart failure ,Pediatrics, Perinatology and Child Health ,Toxicity ,Medicine ,business ,Complication ,Rhabdomyosarcoma - Abstract
Background Doxorubicin cardiotoxicity remains a serious problem in children with malignancy. The present study was undertaken to determine if the administration of consecutive divided daily doses of doxorubicin would significantly reduce the likelihood of cardiotoxicity in children compared with a single dose administration regimen. Procedure One hundred thirteen children (60 boys and 53 girls) received doxorubicin either by single dose infusion or by a consecutive divided daily dose schedule. The divided dose patients received one third of the total cycle dose over 20 minutes for 3 consecutive days. Patients treated according to a single dose schedule received the cycle dose as a 20-minute infusion. The mean doxorubicin dose was 341 mg/m2. Patients were followed up for 4–180 months. There were 60 boys and 53 girls in the series. Results Fifteen patients developed cardiacdysfunction, eight of whom died of progressive cardiac failure. There was no significant difference in the incidence of cardiac dysfunction between the divided and single dose infusion groups. More girls than boys developed cardiac dysfunction and more girls died of progressive cardiac failure; this difference was not statistically significant. The median time to the development of cardiac failure was 2 months. Conclusions The divided dose regimen did not alter the incidence of cardiotoxicity. Other schedules should therefore be investigated. Our data suggest that, at similar cumulative doses, girls are more likely to develop cardiac dysfunction than are boys. If the sex-related difference is proved in larger series of patients, it may be prudent to lower the recommended cumulative doses for girls. Med. Pediatr. Oncol. 31:512–515, 1998. © 1998 Wiley-Liss, Inc.
- Published
- 1998
25. THE CLASSIC: Recent Advances in Chemotherapy of Metastatic Osteogenic Sarcoma
- Author
-
Norman Jaffe and LEONARD F PELTIER
- Subjects
Oncology ,medicine.medical_specialty ,Chemotherapy ,business.industry ,medicine.medical_treatment ,MEDLINE ,Historical Article ,General Medicine ,Internal medicine ,Medicine ,Orthopedics and Sports Medicine ,Surgery ,Metastatic Osteogenic Sarcoma ,business - Published
- 2005
26. Socio-Occupational and Physical Outcomes More than 20 Years after Diagnosis for Osteosarcoma in Children and Adolescents: Limb Salvage versus Amputation
- Author
-
Rhonda Robert, Winston W. Huh, Giulia Ottaviani, Shana L. Palla, and Norman Jaffe
- Subjects
Leiomyosarcoma ,Adult ,Employment ,Male ,Cancer Research ,medicine.medical_specialty ,Pediatrics ,Adolescent ,medicine.medical_treatment ,Bone Neoplasms ,Limb Salvage Procedure ,Article ,Amputation, Surgical ,Young Adult ,Breast cancer ,Postoperative Complications ,Surveys and Questionnaires ,Outcome Assessment, Health Care ,Medicine ,Humans ,Cumulative incidence ,Survivors ,Young adult ,Occupational Health ,Osteosarcoma ,business.industry ,Cancer ,Neoplasms, Second Primary ,Middle Aged ,medicine.disease ,Limb Salvage ,Prognosis ,Surgery ,Oncology ,Amputation ,Social Class ,Marital status ,Female ,business ,Follow-Up Studies - Abstract
BACKGROUND To the best of the authors' knowledge, there has been relatively little research published to date regarding very long-term survivors of childhood and adolescent osteosarcoma. In the current study, the authors compared the very long-term survival outcomes of patients with osteosarcoma who were treated with either limb salvage procedures or amputation. METHODS A total of 38 patients with osteosarcoma who survived ≥ 20 years from the time of diagnosis were divided into 2 groups according to whether they underwent amputation or limb salvage. Participants were asked to complete a questionnaire concerning their education, employment, annual income, marital status, health insurance, lifestyle, siblings, and all current and past health issues. RESULTS Education, employment, marital status, and health insurance were not found to differ significantly between the 2 groups of survivors, who described themselves as being similar to their siblings. Eight percent of survivors underwent secondary amputation because of complications with an endoprosthesis. The cumulative incidence of second primary neoplasms was 13%, and this finding was significantly higher in females and in survivors who underwent radiotherapy and had a genetic predisposition. The second primary malignancies were breast cancer (ductal invasive carcinoma, ductal in situ carcinoma, and leiomyosarcoma), mediastinal leiomyosarcoma, and squamocellular carcinoma of the oral cavity and the uterine cervix. Amputees required more assistive walking support than survivors who received limb salvage treatment (P
- Published
- 2013
27. Conventional and dedifferentiated parosteal osteosarcoma: Diagnosis, treatment, and outcome
- Author
-
Cesar H. Carrasco, A. Kevin Raymond, Dhiren S. Sheth, Norman Jaffe, Alberto G. Ayala, Alan W. Yasko, Robert S. Benjamin, and John A. Murray
- Subjects
Cancer Research ,medicine.medical_specialty ,Chemotherapy ,Medullary cavity ,business.industry ,medicine.medical_treatment ,Wide local excision ,Retrospective cohort study ,Hypervascularity ,medicine.disease ,Surgery ,Oncology ,medicine ,Osteosarcoma ,Sarcoma ,Radiology ,business ,Survival rate - Abstract
BACKGROUND Dedifferentiated parosteal osteosarcoma (dd-POS) designates high grade transformation of conventional low grade parosteal osteosarcoma (c-POS). The paradigm of preoperative diagnosis, neoadjuvant chemotherapy, and wide local excision has not been adequately evaluated for dd-POS, as it has been for conventional high grade intramedullary osteosarcoma. METHODS A retrospective review was conducted of 28 patients treated at the authors' institution between January 1980 and December 1992 for an osteosarcoma arising on the surface of the bone diagnosed as either c-POS or dd-POS. The clinicopathologic features, diagnosis, treatment, and patient outcome were analyzed. RESULTS A dedifferentiated component was identified in 12 of 28 tumors (43%). Neither the presence of radiolucencies (77% in c-POS and 100% in dd-POS, P = 0.06) nor medullary invasion (42% in c-POS and 50% in dd-POS, P = 0.28) distinguished dd-POS from c-POS. However, all patients who presented with focal hypervascularity on an arteriogram defined the high grade component of dd-POS that was confirmed by selective needle biopsy. This differed significantly (P = 0.00003) from c-POS. None of the patients with c-POS died of the disease (median survival duration, 77 months; range, 16–152 months). Six patients (35%) developed a local recurrence, but five were treated successfully with further surgery. In the dd-POS group, 7 of the 12 patients died of the disease. Ten patients with dd-POS received preoperative chemotherapy (IA cis-diamminedichloroplatinum, IV doxorubicin), and a good response (>90% necrosis of high grade component) was observed in four. Among patients whose disease was localized, continuous disease free survival was prolonged significantly (P = 0.03) in patients with a good response (median, 75 months) compared with those who responded poorly (median, 13 months). Five patients remained continuously disease free (median, 66 months; range, 29–95 months). CONCLUSIONS Wide surgical excision alone is adequate treatment for patients with c-POS. Recognition of dedifferentiated areas with angiography and percutaneous biopsy of hypervascular areas should prompt the administration of chemotherapy and wide local excision to optimize patient outcome. Cancer 1996;78:2136-45.
- Published
- 1996
28. The clinical efficacy of intra-arterial and systemic chemotherapy in the treatment of osteosarcoma of children
- Author
-
Norman Jaffe
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Systemic chemotherapy ,medicine.disease ,Rheumatology ,Internal medicine ,Orthopedic surgery ,medicine ,Intra arterial ,Osteosarcoma ,Orthopedics and Sports Medicine ,Surgery ,Clinical efficacy ,business - Published
- 1996
29. Fractionated High-Dose Cyclophosphamide for Advanced Pediatric Solid Tumors
- Author
-
Christian Herzog, Ka Wah Chan, Norman Jaffe, L L Chan, Ayten Cangir, R. B. Raney, J. Ater, and Steven J. Culbert
- Subjects
Male ,medicine.medical_specialty ,Adolescent ,Cyclophosphamide ,medicine.medical_treatment ,Cardiomyopathy ,Sarcoma, Ewing ,Gastroenterology ,Drug Administration Schedule ,Neuroblastoma ,Neoplasms ,Internal medicine ,Granulocyte Colony-Stimulating Factor ,Humans ,Medicine ,Child ,Antineoplastic Agents, Alkylating ,Mesna ,Osteosarcoma ,Chemotherapy ,business.industry ,Infant ,Sarcoma ,Hematology ,medicine.disease ,Surgery ,Ciprofloxacin ,Treatment Outcome ,Oncology ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Toxicity ,Feasibility Studies ,Female ,business ,Uroprotective Agent ,medicine.drug ,Hemorrhagic cystitis - Abstract
Purpose : The objective of this study was to determine the tolerance and toxicities of high-dose cyclophosphamide (CPA) at 7 g/m 2 given in four fractions over 8 h in children with advanced solid tumors. Patients and Methods : Twenty children aged 1 1/2-19 years (median, 12 years) received 24 courses of high-dose CPA at 7 g/m 2 for the treatment of advanced malignant solid tumor. CPA was given in four 1-h infusions of 1.75 g/m 2 each, with 1 h of rest between each dose. MESNA was used as a uroprotective agent and was continued for 24 h after the final dose of CPA. With only one exception, all patients were discharged at the end of MESNA infusion and received granulocyte colony-stimulating factor, prophylactic ciprofloxacin, and co-trimoxazole. Results : Severe but transient myelosuppression was observed. The median time to neutrophil and platelet recovery was 17 and 19 days, respectively. Fever developed after 13 of the 24 courses, and hospitalization was required. Extramedullary toxicities were mild. No patient showed cardiomyopathy or hemorrhagic cystitis. Forty-six percent of the courses were managed entirely on an outpatient basis. Objective tumor response was seen in five patients. Conclusions : CPA at 7 g/m 2 is well tolerated by children with advanced malignancies and should be considered in earlier phases of antineoplastic therapy.
- Published
- 1996
30. Ifosfamide tolerance in osteosarcoma patients previously treated with cis-Diamminedichloroplatinum-II: Renal, hematologic, and neurologic observations
- Author
-
Peggy Pearson, Norman Jaffe, Cengiz Canpolat, and Resa Robertson
- Subjects
Glycosuria ,Cancer Research ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Renal function ,Antineoplastic Agents ,Bone Neoplasms ,Kidney ,Nervous System ,Asymptomatic ,Gastroenterology ,Hypomagnesemia ,Bone Marrow ,Internal medicine ,medicine ,Humans ,Ifosfamide ,Child ,Antineoplastic Agents, Alkylating ,Retrospective Studies ,Osteosarcoma ,Chemotherapy ,Proteinuria ,business.industry ,medicine.disease ,Surgery ,Blood ,Oncology ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Cisplatin ,medicine.symptom ,Complication ,business ,medicine.drug - Abstract
We attempted to ascertain renal, hematologic, and neurologic tolerance to ifosfamide (IFX) in pediatric patients previously treated with large single and cumulative doses of cis-Diamminedichloroplatinum-II (CDP) for osteosarcoma (OS). Twenty OS patients were treated with CDP: initially 150 mg/m2 was administered every 2 weeks for a maximum of seven courses. Later, other agents, including additional CDP, were also administered. Twelve patients were treated with intra-arterial CDP, one with intra-arterial, and later intravenous CDP, and seven with intravenous CDP. Patients who relapsed were treated with IFX. Renal function was monitored by measuring creatinine clearance, serum electrolytes, total protein, albumin and CO2 content, and urine analysis during IFX therapy. Prior to initiation of IFX, creatinine clearance was above 60 ml/min/m2 in all except one patient who had developed a hemolytic uremic syndrome (HUS). Cumulative CDP doses ranged from 300 to 22,500 mg/m2, and cumulative IFX doses 12 to 128 gm/m2. Myelossupression was monitored by obtaining routine hemograms midway between each course of treatment. Neurologic tolerance was assessed by reviewing the medical records for any abnormality. The interval between CDP and IFX ranged from 1 to 64 months. All patients experienced a progressive reduction in creatinine clearance with CDP. The reduction in creatinine clearance, measured from baseline after three to four courses varied from 10 to 53.7%, after four to seven courses from 19 to 78%, and after seven courses from 12 to 80.5%. In all patients except five, including the HUS patient, creatinine clearance remained above 60 ml/min/m2 during IFX therapy. Twelve patients developed hypomagnesemia in the vicinity of 1.4 to 1.6 mg/dl during CDP treatment and required magnesium supplementation. They were asymptomatic and the abnormality did not affect IFX tolerance. Fourteen patients intermittently displayed variable degrees of glycosuria, phosphaturia, and/or proteinuria during IFX therapy. This was considered to be a forma frustre type of Fanconi's syndrome. Approximately 80% of courses of IFX were associated with reversible myelosuppression. No neurologic abnormalities were detected. The abnormalities detected during IFX treatment were not major, did not give rise to symptomatology, and did not require discontinuation of therapy. Renal abnormalities were considered a forma frustre type of Fanconi's syndrome. Provided a creatinine clearance of 60 ml/min/m2 is accepted as a prerequisite for treatment, and no major preexisting renal disease is present, IFX is well tolerated by most patients previously exposed to very high cumulative doses of CDP. © 1996 Wiley-Liss, Inc.
- Published
- 1996
31. Chemotherapy in Osteosarcoma: Basis for Application and Antagonism to Implementation; Early Controversies Surrounding its Implementation
- Author
-
Robert S. Benjamin, Norman Jaffe, and Shreyaskumar Patel
- Subjects
Oncology ,Surgical resection ,medicine.medical_specialty ,Chemotherapy ,business.industry ,Limb salvage ,medicine.medical_treatment ,Hematology ,medicine.disease ,Primary tumor ,Surgery ,Predictive factor ,Internal medicine ,medicine ,Preoperative chemotherapy ,Osteosarcoma ,business - Abstract
Chemotherapy in osteosarcoma has had a major impact in attaining metastasis-free survival, and the cure rates with the use of modern regimens range from 65% to 75%. Preoperative chemotherapy has facilitated surgical resection of the primary tumor, rendering increased numbers of candidates for limb salvage. The effects on the primary tumor may be used as a predictive factor in determining outcome.
- Published
- 1995
32. Combination Therapy with Ifosfamide and Liposome-Encapsulated Muramyl Tripeptide
- Author
-
A. K. Raymond, Shu Fang Jia, Jacalyn B. Gano, Eugenie S. Kleinerman, Norman Jaffe, and Paul A. Meyers
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Adolescent ,Combination therapy ,medicine.medical_treatment ,Immunology ,Neutropenia ,Gastroenterology ,chemistry.chemical_compound ,Adjuvants, Immunologic ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Immunology and Allergy ,Ifosfamide ,Child ,Aged ,Pharmacology ,Osteosarcoma ,Chemotherapy ,business.industry ,Phosphatidylethanolamines ,Neopterin ,Middle Aged ,medicine.disease ,Nitrogen mustard ,Surgery ,chemistry ,Tolerability ,Liposomes ,business ,Acetylmuramyl-Alanyl-Isoglutamine ,Mifamurtide ,medicine.drug - Abstract
A phase IIb trial using liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE) in combination with ifosfamide (IFX) for patients with relapsed osteosarcoma was undertaken to determine (a) the tolerability of the combination therapy, (b) if L-MTP-PE increased the toxicity of IFX, and (c) whether IFX altered or suppressed the in vivo immune response to L-MTP-PE. Patients had histologically proven osteosarcoma and pulmonary metastases that either developed during adjuvant chemotherapy or were present at diagnosis, persisted despite chemotherapy, and recurred following surgical excision. Stratum A patients were rendered clinically free of disease within 4 weeks of study entry prior to receiving combination therapy. IFX was administered at 1.8 g/m2 for 5 days every 21 days for up to eight cycles. L-MTP-PE was administered twice weekly for 12 weeks, then once weekly for 12 weeks. Once cycle of combination therapy was defined as 5 days of IFX and 3 weeks of L-MTP-PE therapy. Stratum B patients had measurable disease at study entry that was judged to be amenable to surgical resection. Stratum B patients received three cycles of combination therapy prior to surgery to judge clinical and histologic response. Postoperatively, patients received an additional five cycles. A total of nine patients were entered into the protocol: six on stratum A and three on stratum B. Serial blood samples were collected and assayed for cytokine levels (tumor necrosis factor-alpha [TNF alpha], interleukin-6 [IL-6], IL-8, neopterin, C-reactive protein). In addition, peripheral blood monocyte tumoricidal activity was evaluated pre- and post-combination therapy. Complete blood counts with differential and platelet counts were followed weekly. No increase in the toxic side effects of IFX was demonstrated when administered with L-MTP-PE nor were delays in IFX administration due to neutropenia experienced. The toxic side effects of L-MTP-PE were also not increased. Elevations of serum C-reactive protein, plasma neopterin, IL-6, IL-8, and TNF alpha following combination therapy were similar to those observed in patients treated with L-MTP-PE alone. Monocyte-mediated tumoricidal activity was elevated 24 and 72 h following L-MTP-PE and IFX therapy, similar to what has been reported following L-MTP-PE alone. Tumor specimens obtained from stratum B patients showed the histologic characteristics consistent with a "chemotherapy effect," i.e., dead, amorphous, acellular osteoid with cell drop-out.(ABSTRACT TRUNCATED AT 400 WORDS)
- Published
- 1995
33. Wilms' tumor: Cure of malignant pleural effusion exclusively with chemotherapy
- Author
-
Norman Jaffe and Cengiz Canpolat
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Pleural effusion ,medicine.medical_treatment ,Thoracentesis ,Wilms Tumor ,Pleural disease ,medicine ,Humans ,Malignant pleural effusion ,Child ,business.industry ,Wilms' tumor ,medicine.disease ,Combined Modality Therapy ,Primary tumor ,Kidney Neoplasms ,Pleural Effusion, Malignant ,Surgery ,Radiation therapy ,Oncology ,Effusion ,Pediatrics, Perinatology and Child Health ,Tomography, X-Ray Computed ,business - Abstract
A malignant pleural effusion was diagnosed by thoracentesis in a 12-year-old patient with an established diagnosis of Wilms' tumor. He was treated with chemotherapy and achieved a reduction in the size of the primary tumor and resolution of the effusion. The primary tumor was then resected and chemotherapy continued for a total of 18 months. At the request of the parents, radiation therapy to the thorax was withheld. The patient has remained free of disease for the past 8 years. © 1995 Wi1ey-Liss Inc.
- Published
- 1995
34. Cisplatin-Associated hemolytic uremic syndrome
- Author
-
Norman Jaffe, Cengiz Canpolat, and Peggy Pearson
- Subjects
Male ,Hemolytic anemia ,Cancer Research ,medicine.medical_specialty ,Time Factors ,Adolescent ,medicine.medical_treatment ,Bone Neoplasms ,Gastroenterology ,Internal medicine ,medicine ,Humans ,Cisplatin ,Osteosarcoma ,Chemotherapy ,Tibia ,business.industry ,Bilirubin ,Microangiopathic hemolytic anemia ,medicine.disease ,Oncology ,Creatinine ,Hemolytic-Uremic Syndrome ,Immunology ,Etiology ,Hemodialysis ,Complication ,business ,medicine.drug - Abstract
Background. Hemolytic uremic syndrome (HUS) is an acquired disorder largely affecting infants and young children. It is characterized by the triad of microangiopathic hemolytic anemia, acute renal failure, and thrombocytopenia. Although its etiology is unknown, viral and bacterial infections, disseminated malignancies in adults, and a variety of chemotherapeutic agents including cisplatin, have been implicated in its occurrence. The association of HUS with chemotherapeutic agents after its detection in a pediatric patient treated with cisplatin is reviewed. Methods. A 16-year-old male with osteosarcoma was treated with cisplatin as part of a chemotherapy protocol. After the fourth course, his renal function deteriorated and necessitated cessation of cisplatin. Nine months after the initiation of cisplatin, HUS developed. There was no evidence of residual tumor or metastatic disease. He received numerous packed erythrocyte and platelet transfusions for persistent hemolysis and underwent several episodes of hemodialysis. Utilizing this patient as an example, the authors reviewed the incidence of HUS developing subsequent to the use of other chemotherapeutic agents. Results. In the publishing literature, chemotherapy-associated HUS has been described to occur 54 days to 14 months after the initiation of chemotherapeutic regimens. A variety of agents was associated with the phenomenon. Conclusion. Hemolytic uremic syndrome may be a complication of cisplatin, as evidenced by the condition that occurred in a 16-year-old patient with osteosarcoma after cisplatin therapy.
- Published
- 1994
35. Long-term effects of radiotherapy administered in childhood for the treatment of malignant diseases
- Author
-
Hubert L. Ried, Stephen S. Kroll, David L. Larson, Antonio Santin, Hallie Zietz, Norman Jaffe, and Shiao Y. Woo
- Subjects
Male ,medicine.medical_specialty ,Neoplasms, Radiation-Induced ,Soft Tissue Injuries ,Time Factors ,Adolescent ,medicine.medical_treatment ,Endocrine System Diseases ,Malignancy ,Surgical oncology ,Neoplasms ,medicine ,Humans ,Endocrine system ,Child ,Radiation Injuries ,Growth Disorders ,Skin ,business.industry ,Medical record ,Incidence (epidemiology) ,Infant ,Neoplasms, Second Primary ,Radiotherapy Dosage ,medicine.disease ,Combined Modality Therapy ,Hypoplasia ,Surgery ,Radiation therapy ,Oncology ,Chemotherapy, Adjuvant ,Child, Preschool ,Female ,Atrophy ,business ,Follow-Up Studies ,Hormone - Abstract
Background: The use of radiotherapy for the treatment of childhood malignancy has improved long-term survival significantly, and many treated children now survive well into adulthood. As a consequence, long-term effects of childhood irradiation are being seen with increasing frequency. Methods: The medical records of 236 patients who had been treated for malignant disease with radiotherapy during childhood were examined to determine the long-term effect of the radiation on their growth and development. Results: Mean treatment dose was 35.5 Gy; mean age at treatment was 7.2 years; and mean follow-up was 14.5 years. Adjuvant chemotherapy was given to 82%. Some degree of bone deformity (usually with overlying soft-tissue hypoplasia) was seen in 40%; 21% developed some type of endocrine deficiency; 30% developed atrophic skin changes; and 7% developed second malignancies. The incidence of bone deformity and hormonal deficiency increased with the radiation dose; the incidence of second malignancy was independent of dose. Bone deformities were more common when radiation was administered before the age of 2 years. Conclusions: The consequences of radiotherapy in childhood are significant and must be considered when planning treatment. Even when treatment is essential, families should be informed of the possibility of growth disturbance to prevent subsequent misunderstanding.
- Published
- 1994
36. Radiation-induced changes in long-term survivors of childhood cancer after treatment with radiation therapy
- Author
-
Norman Jaffe and Hubert L. Ried
- Subjects
Lung Diseases ,Male ,medicine.medical_specialty ,Neoplasms, Radiation-Induced ,Sterility ,Developmental Disabilities ,medicine.medical_treatment ,Childhood cancer ,Early detection ,Radiation induced ,Neoplasms ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Intensive care medicine ,Brain Diseases ,Chemotherapy ,Radiotherapy ,business.industry ,Infant ,Surgery ,Radiation therapy ,Cardiovascular Diseases ,Child, Preschool ,Female ,Meningioma ,business ,Complication ,After treatment - Abstract
Summary This article has provided an account of the delayed effects after successful treatment for childhood cancer. Particular emphasis has been placed on sequelae induced by radiation therapy. Chemotherapy-related complications that may simulate or aggravate these sequelae also are recorded. The alterations induced by radiation therapy and chemotherapy are not limited to the organs and tissues described in this article. Subtle, and at times psychologically devastating, sequelae also may be encountered (eg, sterility due to radiation and chemotherapeutic effects on the gonads). However, an attempt has been made only to identify those complications that may be more readily detected by means of radiographic studies. It is recommended that ongoing surveillance of the long-term successfully treated childhood cancer survivor be conducted in order to detect such complications. Early detection will assist in implementing appropriate treatment, minimizing delayed effects, and maximizing the quality of life. Periodic radiographic studies of previously radiated areas at regular intervals therefore appears appropriate.
- Published
- 1994
37. Is there a safe therapeutic window for delivery of chemotherapy prior to initiation of surgery and/or radiation-therapy for treatment of the primary tumor in children with rhabdomyosarcoma
- Author
-
Sy Woo, T Black, Ej Rott, Mh Maor, Norman Jaffe, Rj Andrassy, and M Smith
- Subjects
Therapeutic window ,Cancer Research ,Chemotherapy ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Incidence (epidemiology) ,Cancer ,medicine.disease ,Primary tumor ,Discontinuation ,Surgery ,Radiation therapy ,Oncology ,medicine ,business ,Rhabdomyosarcoma - Abstract
To avoid the delayed consequences of treatment with radiotherapy, an effort was made to determine if patients with rhabdomyosarcoma could be cured with chemotherapy as the sole form of treatment. Alternatively, if radiotherapy and/or surgery were required to reduce the severity and incidence of delayed sequelae, an effort was made to determine if there was an optimum safe period for delaying implementation of these definitive forms of treatment. In patients where primary (immediate) definitive non-mutilating surgical extirpation of tumor was not feasible, exclusive treatment with chemotherapy was implemented. If considered necessary or appropriate, delayed surgery and/or radiation therapy were employed in 3 circumstances: (i) to consolidate a partial response; (ii) failure to respond; (iii) recurrent disease. The outcome of the delays prior to the implementation of definitive therapy was analyzed as a function of local and systemic recurrence and cure. Fifty-two patients were evaluated. Seven underwent primary non-mutilating surgical extirpation of localized tumor followed by adjuvant chemotherapy. The remaining 45 were treated with primary chemotherapy and 44 responded. Actuarial survival curves of the delay in initiating definitive therapy in the 52 patients revealed that the optimum delay to attain the best survival was 5 months. In circumstances where definitive therapy was not electively introduced, recurrent disease during remission appeared between 7 and 14 months in 7 patients on continued treatment, and in one patient at 30 months, 8 months after discontinuation of chemotherapy. Based upon the 5-month delay an analysis of survival was performed: Definitive therapy was introduced in 14 patients within 5 months and 7 were cured. In the remaining 31 patients, definitive therapy was introduced between 5 and 30 months and 15 were cured. The five month delay is supported empirically by tumor doubling times. No patient was cured exclusively with chemotherapy.
- Published
- 2011
38. Forty-year experience with second malignancies after treatment of childhood cancer: Analysis of outcome following the development of the second malignancy
- Author
-
Mark B. Smith, Louise C. Strong, Hallie Zietz, Richard J. Andrassy, Norman Jaffe, Hiroshi Takahashi, Hasen Xue, and Hugh Ried
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,Time Factors ,Adolescent ,medicine.medical_treatment ,medicine.disease_cause ,Breast cancer ,Neoplasms ,Internal medicine ,medicine ,Humans ,Child ,Thyroid neoplasm ,Chemotherapy ,business.industry ,Incidence ,Soft tissue sarcoma ,Neoplasms, Second Primary ,General Medicine ,Prognosis ,medicine.disease ,Combined Modality Therapy ,Texas ,Lymphoma ,Surgery ,Radiation therapy ,Leukemia ,Treatment Outcome ,Pediatrics, Perinatology and Child Health ,Female ,Skin cancer ,business ,Follow-Up Studies - Abstract
As the cure rate for childhood malignancies increases, the number of patients at risk for development of second malignancies also increases. Due to the potentially long remaining life span, long-term follow-up is difficult and patients are often at risk after presumptive cures. Some authors believe that cure rates for second malignancies are similar to cure rates for primary malignancies. We reviewed the records of 162 patients seen at our institution who had developed a second malignancy after treatment for childhood cancer. Presentation, age at diagnosis, tumor histology, extent of tumor, treatment (including radiotherapy with dosage when available, and chemotherapy) plus outcome were recorded. Mean age at diagnosis of the primary malignancy was 10.3 years. The most common primary malignancy was Hodgkin's disease (33) followed by soft tissue sarcoma (28), retinoblastoma (20), bone tumor (17), central nervous system (CNS) tumor (13), leukemia (8), Wilms' tumor (7), non-Hodgkin's lymphoma (6), neuroblastoma (5), thyroid neoplasm (5), and others (20). The average interval between diagnosis of the first and second malignancy was 10.8 years. These second tumors carried a high mortality. Only 56 patients have no evidence of disease. Five patients are known to be alive with disease and 92 patients have expired due to their second malignancy. Disease status in 8 patients is unknown. The most common second malignancy was osteosarcoma (35) followed by soft tissue sarcoma (24), breast cancer (15), leukemia (14), thyroid carcinoma (14), CNS tumors (12), melanoma (8), nonmelanomatous skin cancer (8), lymphoma (5), and others (27). Eighteen of 35 bone sarcomas developed in irradiated fields and the mean dosage was 44.0±16.3 (10 to 64 Gy). Seventeen of 19 patients who developed a hematologic malignancy received an alkylating agent when treated for their primary malignancy. Of 162 patients developing second malignancies, only 34.6% were cured. When patients with thyroid lesions are excluded, only 28.9% were cured. These poor results are most likely due to two main factors: (1) a high percentage of tumors were not able to be cured due to local unresectability, and (2) the biology of many of these lesions is more aggressive than similar tumors arising "de novo." The more aggressive nature of these neoplasms may in part be due to genetic mutations present at the time of initial diagnosis and/or due to DNA damage resulting from irradiation or administration of alkylating agents.
- Published
- 1993
39. Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A pediatric oncology group phase II study
- Author
-
Barry Golembe, Molly Schwenn, Faith H. Kung, Mark Bernstein, C. Tate Holbrook, Jeffrey P. Krischer, Charles B. Pratt, Ruprecht Nitschke, Alan C. Homans, Roger A. Vega, Norman Jaffe, and Douglas Strother
- Subjects
Cancer Research ,medicine.medical_specialty ,Chemotherapy ,Ifosfamide ,business.industry ,medicine.medical_treatment ,Phases of clinical research ,medicine.disease ,Gastroenterology ,Surgery ,Nephrotoxicity ,Sepsis ,Oncology ,Internal medicine ,medicine ,Absolute neutrophil count ,business ,Etoposide ,Mesna ,medicine.drug - Abstract
Background. The prognosis for children with recurrent or resistant malignant solid tumors remains dismal. More effective rescue therapy is needed for these children. Methods. Between August 1987 and November 1990, 311 children with recurrent or resistant malignant solid tumors were treated by investigators in the Pediatric Oncology Group with intravenous infusions of 2.0 g/m2 of ifosfamide and 100 mg/m2 of etoposide (VP-16) plus mesna as uroprotection three times daily, with courses being repeated every 14–21 days for as long as the patients responded to therapy. Results. Seventy-four percent of the 294 assessable patients entered in the study had metastatic disease and previously had been treated heavily. The complete response/partial response rate was 30%, and the overall response rate was 39.5%. Toxic effects included nephrotoxicity, mild liver dysfunction, neurotoxicity, and myelosuppression. Sixty-eight percent had an absolute neutrophil count (ANC) of less than 500/μl. In 1606 courses of therapy administered, only 3.6% of patients developed a bacterial infection. Only two patients died of gram-negative sepsis. Four percent of the patients had gross hematuria (> 50 erythrocytes/high-power field), and 18.5% had microscopic hematuria (< 20 erythrocytes/high-power field). Fanconi syndrome developed in eight children. Conclusions. Ifosfamide/VP-16 is an active combination in children with recurrent malignant solid tumors. Although it was myelosuppressive, the incidence of infection was quite low (3.6%). Mesna was very effective in preventing the development of hematuria.
- Published
- 1993
40. Editorial summation. What have we learned, where do we stand and where do we go from here?
- Author
-
Norman, Jaffe
- Subjects
Osteosarcoma ,Animals ,Humans ,Bone Neoplasms - Published
- 2010
41. The etiology of osteosarcoma
- Author
-
Giulia, Ottaviani and Norman, Jaffe
- Subjects
Alkylating Agents ,Osteosarcoma ,Neoplasms, Radiation-Induced ,Humans ,Bone Neoplasms - Abstract
Studies to determine the etiology of osteosarcoma involve epidemiologic and environmental factors and genetic impairments. Factors related to patient characteristics include age, gender, ethnicity, growth and height, genetic and familial factors, and preexisting bone abnormalities. Rapidly proliferating cells may be particularly susceptible to oncogenic agents and mitotic errors which lead to neoplastic transformation. Genetic aberrations that accompany osteosarcoma have received increasing recognition as an important factor in its etiology. Osteosarcoma tumor cells exhibit karyotypes with a high degree of complexity which has made it difficult to determine whether any recurrent chromosomal aberrations characterize osteosarcoma. Although extremely rare, osteosarcoma has occasionally been observed in several members of the same family. No other clinical abnormalities in the proband or the affected members were reported. Pathologic examination of the tumors revealed no unusual features. Genetic testing was not available in most of these reports. The patients generally responded to conventional therapy. A genetic predisposition to osteosarcoma is found in patients with hereditary retinoblastoma, characterized by mutation of the retinoblastoma gene RB1 on chromosome 13q14. The Rothmund-Thomson syndrome is an autosomal recessive disorder with a heterogeneous clinical profile. Patients may have a few or multiple clinical features including skin rash, small stature, skeletal dysplasias, sparse or absent scalp hair, eyebrows or eyelashes, juvenile cataracts, and gastrointestinal disturbance including chronic emesis and diarrhea; its molecular basis is the mutation in the RECQL4 gene in a subset of cases. The Li-Fraumeni syndrome is an autosomal dominant disorder characterized by a high risk of developing osteosarcoma and has been found in up to 3% of children with osteosarcoma. It is associated with a germline mutation of the p53, a suppressor gene. The following three criteria must be met for a diagnosis of Li-Fraumeni syndrome: (1) A proband diagnosed with sarcoma when younger than 45 years; (2) A first-degree relative with any cancer diagnosed when younger than 45 years; (3) Another first- or second-degree relative of the same genetic lineage with any cancer diagnosed when younger than 45 years or sarcoma diagnosed at any age. A second recessive p53 oncogene on chromosome 17p13.1 may also play a role in the development and progression of osteosarcoma. Osteosarcoma has also been associated with solitary or multiple osteochondroma, solitary enchondroma or enchondromatosis (Ollier's disease), multiple hereditary exostoses, fibrous dysplasia, chronic osteomyelitis, sites of bone infarcts, sites of metallic prostheses and sites of prior internal fixation. Ionizing radiation is a well-documented etiologic factor. Osteosarcoma has also been associated with the use of intravenous radium and Thorotrast. Exposure to alkylating agents may also contribute to its development ,and it is apparently independent of the administration of radiotherapy.
- Published
- 2010
42. Functional, psychosocial and professional outcomes in long-term survivors of lower-extremity osteosarcomas: amputation versus limb salvage
- Author
-
Giulia, Ottaviani, Rhonda S, Robert, Winston W, Huh, and Norman, Jaffe
- Subjects
Employment ,Reoperation ,Osteosarcoma ,Lower Extremity ,Quality of Life ,Humans ,Bone Neoplasms ,Survivors ,Limb Salvage ,Amputation, Surgical - Abstract
As the number of osteosarcoma survivors increases, the impact of quality of life and function needs to be addressed. Limb salvage is the preferred treatment when patients have treatment options; yet, the questionable long-term durability and complications of prostheses, combined with ambiguous function, leave some doubt regarding the best clinical and surgical options. Comparisons between limb salvage patients, amputees and controls also require further investigation. Amputation would leave the patients with a lifelong requirement for an external prosthetic leg associated with an overall limited walking distance. While artificial limbs are much more sophisticated than those used in the past, phantom limb sensations remain a substantial and unpredictable problem in the amputee. Complications such as stump overgrowth, bleeding, and infection, also require further elucidation. Limb salvage surgery using endoprosthesis, allografts or reconstruction is performed in approximately 85% of patients affected by osteosarcoma located in the middle and/or distal femur. One drawback in limb-salvage surgery in the long-term survivor is that endoprostheses have a limited life span with long-term prosthetic failure. The inherent high rate of reoperation remains a serious problem. Replacing a damaged, infected or severely worn-out arthroplastic joint or its intramedullary stem is difficult, especially in the long-stem cemented endoprostheses used in the 1980s. Limb lengthening procedures in patients who have not reached maturity must also be addressed. Periprosthetic infections, compared to other indications for joint reconstruction, were found to be more frequent in patients treated for neoplastic conditions and their outcome can be devastating, resulting in total loss of joint function, amputation, and systemic complications. Quality of life in terms of function, psychological outcome and endpoint achievements such as marriage and employment apparently do not differ significantly between amputee and nonamputee osteosarcoma survivors. Amputee patients nonetheless appear to have made satisfactory adjustments to their deficits with or without a functional external prosthesis. It also appeared that amputee patients had a similar psychological and quality of life outcome as limb salvage patients. There was no evidence of excessive anxiety or depression or deficits in self-esteem compared with the normal population or matched controls. A number of long-term survivors also achieved high ranking in the professional and commercial work place. These positive aspects should be recognized and emphasized to patients and their parents when discussing the outcome.
- Published
- 2010
43. Osteosarcoma multidisciplinary approach to the management from the pathologist's perspective
- Author
-
A Kevin, Raymond and Norman, Jaffe
- Subjects
Male ,Osteosarcoma ,Biopsy ,Humans ,Bone Neoplasms ,Female - Abstract
Osteosarcoma is a primary malignant tumor of the bone in which proliferating neoplastic cells produce osteoid and/or bone, if only in small amounts. This histological principle defines a tumor that usually affects young males more frequently than females, and disproportionately involves the long bones of the appendicular skeleton. These tumors are generally locally aggressive and tend to produce early, lethal systemic metastases. However, osteosarcoma is not a single disease but a family of neoplasms, sharing the single histological finding of osseous matrix production in association with malignant cells. The majority (i.e., 75%) of cases are relatively stereotypical from the demographic, clinical, radiographic and histologic points of view. These tumors generally occur in the metaphyseal portion of the medullary cavity of the long bone and are referred to as "Conventional Osteosarcoma." The group is sub classified by the form of the dominant matrix present within the tumor, which may be bone, cartilage or fibrous tissue, and it is correspondingly referred to as osteoblastic, chondroblastic and fibroblastic osteosarcoma. The remaining 25% of cases have unique parameters that allow reproducible identification of tumors which are biologically different from conventional osteosarcoma and are referred to as "Variants." The parameters identifying Variants fall into one of three major groups: (1) clinical factors, (2) histologic findings and (3) location of origin--within or on the cortex. Because of their inherent biological difference from Conventional Osteosarcoma, the Variants identify cases which must be excluded from analysis of data pertaining to the treatment of the majority of cases: Conventional Osteosarcoma. The diagnostic parameters of osteosarcoma must be sufficiently inclusive to identify all the members of this potentially lethal tumor. Conversely, criteria for sub classification must be restricted to assure homogenous populations of tumors productively incorporating different biological behavior and the potential for development of unique treatment strategies which are different from those for Conventional Osteosarcoma. This can be designated "Classification Based Therapy" or "Therapy Based Osteosarcoma." With this background, we will discuss the highly disciplined approach to the management of osteosarcoma from the pathologist's perspective. Factors governing the assessment of the response to preoperative chemotherapy will also be reviewed.
- Published
- 2010
44. Conditions that mimic osteosarcoma
- Author
-
A Kevin, Raymond and Norman, Jaffe
- Subjects
Diagnosis, Differential ,Giant Cell Tumor of Bone ,Bone Cysts, Aneurysmal ,Osteosarcoma ,Fibroma, Ossifying ,Chondrosarcoma ,Humans ,Bone Neoplasms ,Sarcoma, Ewing - Abstract
A variety of conditions may mimic osteosarcoma. The differential diagnosis includes benign and malignant tumors, infection and inflammatory processes arising from the musculoskeletal system. An accurate clinical history, imaging studies, and pathological evaluation are essential to establish the exact diagnosis. This chapter describes many of the conditions which may mimic the diagnosis of osteosarcoma. For convenience, the conditions are divided into several categories.
- Published
- 2010
45. Osteosarcoma: review of the past, impact on the future. The American experience
- Author
-
Norman, Jaffe
- Subjects
Osteosarcoma ,Methotrexate ,Doxorubicin ,Antineoplastic Combined Chemotherapy Protocols ,Leucovorin ,Humans ,Bone Neoplasms ,Cisplatin ,Cyclophosphamide - Abstract
Major advances have been achieved in the treatment of osteosarcoma with the discovery of several chemotherapeutic agents that were active in the disease. These agents comprise high-dose methotrexate with leucovorin rescue, Adriamycin, cisplatin, ifosfamide and cyclophosphamide. The agents were integrated into various regimens and administered in an effort to destroy silent pulmonary micrometastases which are considered to be present in at least 80% of patients at the time of diagnosis. Their efficacy in achieving this goal was realized and their use was further extended to the application of preoperative (neoadjuvant) chemotherapy to destroy the primary tumor and achieve safe surgical resections. Disease free survival was escalated from20% prior to the introduction of effective chemotherapy to 55-75% and overall survival to 85%. Further, the opportunity to perform limb salvage was expanded to 80% of patients. Of interest also was an attempt in one series to treat the primary tumor exclusively with chemotherapy, and abrogation of surgery. Adding to these advances, varieties of subsequently discovered agents are currently undergoing investigations in patients who have relapsed and/or failed conventional therapy. The agents include Gemcitabine, Docetaxel, novel antifolate compounds, and a liposome formulation of adriamycin (Doxil). A biological agent, muramyl tripeptide phosphatidyl ethanolamine (MTPPE) was also recently investigated in a 2x2 factorial design to determine its efficacy in combination with chemotherapy (methotrexate, cisplatin, Adriamycin and ifosfamide).In circumstances where the tumor was considered inoperable, chemotherapy and radiotherapy were advocated for local control. High dose methotrexate, Adriamycin and cisplatin and Gemcitabine interact with radiation therapy and potentiate its therapeutic effect. This combination is also particularly useful in palliation. Occasionally, the combination of radiation and chemotherapy may render a tumor suitable for surgical ablation. Samarium153, a radio active agent, is also used as palliative therapy for bone metastases.However, despite the advances achieved with the multidisciplinary application of chemotherapy, radiotherapy and surgical ablation of the primary tumor over the past 3(1/2) decades, the improved cure rate reported initially has not altered. Particularly vexing is the problem of rescuing patients who develop pulmonary metastases after receiving seemingly effective multidisciplinary treatment. Approximately 15-25% of such patients only are rendered free of disease with the reintroduction of chemotherapy and resection of metastases. Extrapulmonary metastases and multifocal osteosarcoma also constitute a major problem. The arsenal of available agents to treat such patients has not made any substantial impact in improving their survival. New chemotherapeutic agents are urgently required to improve treatment and outcome. Additional strategies to be considered are targeted tumor therapy, anti tumor angiogenesis, biotherapy and therapy based upon molecular profiles. This communication outlines sequential discoveries in the chemotherapeutic research of osteosarcoma in the United States of America. It also describes the principles regulating the therapeutic application of the regimens and considers the impact of their results on the conduct in the design of future investigations and treatment.
- Published
- 2010
46. Adjuvant chemotherapy in osteosarcoma: an odyssey of rejection and vindication
- Author
-
Norman, Jaffe
- Subjects
Osteosarcoma ,Chemotherapy, Adjuvant ,Humans ,Bone Neoplasms - Published
- 2010
47. Pediatric and Adolescent Osteosarcoma
- Author
-
Norman Jaffe, S. Bielack, and Øyvind S. Bruland
- Subjects
musculoskeletal diseases ,Oncology ,medicine.medical_specialty ,Chemotherapy ,business.industry ,medicine.medical_treatment ,Multimodal therapy ,medicine.disease ,Surgery ,Radiation therapy ,medicine.anatomical_structure ,Childhood Osteosarcoma ,Quality of life ,Internal medicine ,medicine ,Osteosarcoma ,Bone marrow ,Sarcoma ,business ,neoplasms - Abstract
General Aspects of Osteosarcoma.- The Epidemiology of Osteosarcoma.- The Etiology of Osteosarcoma.- Imaging Assessment of Osteosarcoma in Childhood and Adolescence: Diagnosis, Staging, and Evaluating Response to Chemotherapy.- Osteosarcoma Multidisciplinary Approach to the Management from the Pathologist's Perspective.- Conditions that Mimic Osteosarcoma.- Treatment.- Surgical Management of Primary Osteosarcoma.- The Role of Radiotherapy in Oseosarcoma.- Osteosarcoma Lung Metastases Detection and Principles of Multimodal Therapy.- Surgical Treatment of Pulmonary Metastases from Osteosarcoma in Pediatric and Adolescent Patients.- Non-Surgical Treatment of Pulmonary and Extra-pulmonary Metastases.- Review of the Past, Impact on the Future.- Adjuvant Chemotherapy in Osteosarcoma.- Osteosarcoma: Review of the Past, Impact on the Future. The American Experience.- Osteosarcoma: The European Osteosarcoma Intergroup (EOI) Perspective.- The Treatment of Nonmetastatic High Grade Osteosarcoma of the Extremity: Review of the Italian Rizzoli Experience. Impact on the Future.- Osteosarcoma: The COSS Experience.- Treatment of Osteosarcoma. The Scandinavian Sarcoma Group Experience.- Childhood Osteosarcoma: Multimodal Therapy in a Single-Institution Turkish Series.- International Collaboration is Feasible in Trials for Rare Conditions: The EURAMOS Experience.- Pediatric and Adult Osteosarcoma: Comparisons and Contrasts in Presentation and Therapy.- Supportive Care and Quality of Life.- The Role of Physical Therapy and Occupational Therapy in the Rehabilitation of Pediatric and Adolescent Patients with Osteosarcoma.- Caring for Children and Adolescents with Osteosarcoma: A Nursing Perspective.- Prosthetics for Pediatric and Adolescent Amputees.- Functional, Psychosocial and Professional Outcomes in Long-Term Survivors of Lower-Extremity Osteosarcomas: Amputation Versus Limb Salvage.- Research and Investigation: New and Innovative Strategies.- Bridging the Gap Between Experimental Animals and Humans in Osteosarcoma.- Is There a Role for Immunotherapy in Osteosarcoma?.- Molecular Classification of Osteosarcoma.- Current Concepts on the Molecular Biology of Osteosarcoma.- How the NOTCH Pathway Contributes to the Ability of Osteosarcoma Cells to Metastasize.- The Role of Fas/FasL in the Metastatic Potential of Osteosarcoma and Targeting this Pathway for the Treatment of Osteosarcoma Lung Metastases.- Bone Marrow Micrometastases Studied by an Immunomagnetic Isolation Procedure in Extremity Localized Non-metastatic Osteosarcoma Patients.- Strategies to Explore New Approaches in the Investigation and Treatment of Osteosarcoma.- History of Orthopedic Oncology in the United States.
- Published
- 2010
48. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration
- Author
-
Robert S. Benjamin, Eugenie S. Kleinerman, Shu Fang Jia, Norman Jaffe, Nita L. Seibel, and Janet R. Griffin
- Subjects
Cancer Research ,Lung Neoplasms ,medicine.medical_treatment ,Alpha (ethology) ,Antineoplastic Agents ,Pharmacology ,Neopterin ,chemistry.chemical_compound ,medicine ,Humans ,Drug Carriers ,Osteosarcoma ,Chemotherapy ,business.industry ,Phosphatidylethanolamines ,Monocyte ,medicine.disease ,Biopterin ,C-Reactive Protein ,Cytokine ,medicine.anatomical_structure ,Oncology ,chemistry ,Liposomes ,Immunology ,Cytokines ,Drug Evaluation ,Tumor necrosis factor alpha ,Monocytes, Activated Killer ,business ,Acetylmuramyl-Alanyl-Isoglutamine ,Mifamurtide - Abstract
PURPOSE A phase II trial that uses liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE) in patients with relapsed osteosarcoma is underway. To determine if in vivo cytokine induction plays a role in the mechanism of action of L-MTP-PE, we investigated the circulating cytokine levels of 16 patients who were undergoing therapy. PATIENTS AND METHODS Patients had histologically proven osteosarcoma and pulmonary metastases that developed either during adjuvant chemotherapy or that were present at diagnosis and persisted despite chemotherapy. Patients were rendered disease-free by surgery. The major goal of the study was to improve the disease-free interval in this high-risk group. L-MTP-PE 2 mg/m2 was infused during a 1-hour period twice a week for 12 weeks, then once a week for 12 weeks. Serial blood samples were collected after L-MTP-PE administration and were assayed for cytokine levels (tumor necrosis factor-alpha [TNF alpha] interleukin-1 alpha [IL-1 alpha], IL-1 beta, IL-6, interferon-gamma [IFN-gamma], neopterin, C-reactive protein). RESULTS After the infusion of L-MTP-PE, there was rapid induction of circulating TNF alpha and IL-6. TNF alpha levels peaked 1 to 2 hours after infusion in 10 of 16 patients, whereas peak IL-6 levels were detected at 2 to 3 hours in all patients. Induction of circulating TNF alpha and IL-6 was evident only after the first dose of L-MTP-PE. Neither IL-1 alpha nor IL-1 beta was detected in the plasma. Neopterin levels increased at 24 hours postinfusion, which indicated macrophage activation, and were not related to the induction of circulating IFN-gamma. C-reactive protein was elevated in all patients at 24 hours and decreased by 72 hours. Unlike circulating TNF alpha and IL-6, elevations in C-reactive protein and neopterin could be detected throughout the treatment course. CONCLUSION It is concluded that L-MTP-PE has specific biologic effects in patients with osteosarcoma that may be important to the drug's immunostimulatory capacity and its effectiveness as an antitumor agent.
- Published
- 1992
49. Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid)
- Author
-
Michael E. Harris, Robert S. Benjamin, Corazon D. Bucana, Norman Jaffe, A. K. Raymond, Eugenie S. Kleinerman, Irwin H. Krakoff, and Isaiah J. Fidler
- Subjects
Adult ,Male ,Cancer Research ,Pathology ,medicine.medical_specialty ,Lung Neoplasms ,Adolescent ,medicine.medical_treatment ,Immunology ,Metastasis ,Neovascularization ,Adjuvants, Immunologic ,Fibrosis ,medicine ,Humans ,Immunology and Allergy ,Osteosarcoma ,Chemotherapy ,Lung ,business.industry ,Phosphatidylethanolamines ,Respiratory disease ,Immunotherapy ,medicine.disease ,medicine.anatomical_structure ,Oncology ,Chemotherapy, Adjuvant ,Liposomes ,Female ,medicine.symptom ,business ,Acetylmuramyl-Alanyl-Isoglutamine - Abstract
We have recently begun a phase II trial in patients with osteosarcoma who developed pulmonary metastases during adjuvant chemotherapy or who presented with pulmonary metastases that persisted despite chemotherapy. Eligible patients were rendered free of visible disease by surgery. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (MTP-PE, CGP 19835A lipid) (2 mg/m2) was infused twice weekly for 3 months. In five patients, a single tumor nodule recurred within 6 weeks after completion of therapy. These lesions were resected and submitted for pathological examination. Tissue specimens obtained after therapy were compared to those obtained before therapy. All the patients showed a histological change in the characteristics of the pulmonary tumors. In three patients, peripheral fibrosis surrounded the tumor and inflammatory cell infiltration and neovascularization were present. This is in contrast to central necrosis, with viable peripheral tumor cells and no inflammatory response observed in lesions resected following chemotherapy. In a fourth case, evidence of early fibrotic changes was found. This and the fifth case showed a change in malignant characteristics, from high grade before liposomal therapy to low grade after therapy. The present study provides evidence for a biological effect of liposomal MTP-PE.
- Published
- 1992
50. Secondary acute non-lymphoblastic leukemia in two children following treatment with a cis-diamminedichloroplatinum-II-based regimen for osteosarcoma
- Author
-
Norman Jaffe, Sima Jeha, and Resa Robertson
- Subjects
Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Vincristine ,Pathology ,Myeloid ,Adolescent ,Leucovorin ,Leukemia, Myelomonocytic, Acute ,Myelogenous ,hemic and lymphatic diseases ,Internal medicine ,Humans ,Medicine ,Child ,Osteosarcoma ,business.industry ,Neoplasms, Second Primary ,medicine.disease ,Leukemia, Myeloid, Acute ,Regimen ,Leukemia ,Methotrexate ,medicine.anatomical_structure ,Pediatrics, Perinatology and Child Health ,Female ,Cisplatin ,business ,Complication ,medicine.drug - Abstract
Acute nonlymphocytic leukemia (ANLL) developed in 2 of 142 pediatric patients with osteosarcoma treated with a cis-diamminedichloroplatinum-II (CDP)-based regimen: acute monomyelogenous leukemia (M4) with a normal female karyotype in one and acute myelogenous leukemia (M2) with t (8,21) in the other. The ANLLs occurred, respectively, in each patient 3 and 4 years after the initial diagnosis of osteosarcoma. In contrast to most of the adult experience and consistent with the majority of reported ANLL in children, the disease was characterized by an absence of the smoldering phase and cytogenetic findings similar to those seen in de novo ANLL.
- Published
- 1992
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.